B
VRDN icon

Braidwell’s Viridian Therapeutics VRDN Stock Holding History

Braidwell’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34,094
Closed -$654K – 78
2024
Q4 		$654K Buy
+34,094
New +$741K 0.02% 73
2024
Q1 		– Sell
-323,102
Closed -$7.04M – 82
2023
Q4 		$7.04M Sell
323,102
-1,412,080
-81% -$22.3M 0.26% 66
2023
Q3 		$26.6M Buy
1,735,182
+528,882
+44% +$10.1M 0.84% 40
2023
Q2 		$28.7M Buy
+1,206,300
New +$30.9M 0.94% 38
2023
Q1 		– Sell
-313,403
Closed -$9.15M – 98
2022
Q4 		$9.15M Buy
+313,403
New +$7.22M 0.31% 73

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Braidwell's VRDN Position: Q1 2025 in Review

Braidwell sold out of Viridian Therapeutics (VRDN) in Q1 2025, closing a stake of 34,094 shares — an estimated $654K sold.

Braidwell first reported a position in VRDN in Q4 2022 and held it in 5 quarters. The position peaked at $28.7M in Q2 2023. 176 funds tracked by Wall St. Rank hold VRDN as of Q1 2025.

  • Braidwell reported no remaining Viridian Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Braidwell sold 34,094 Viridian Therapeutics shares in Q1 2025, an estimated $654K.
  • Braidwell first reported a position in Viridian Therapeutics in Q4 2022 and held it in 5 quarters.
  • Braidwell's Viridian Therapeutics position peaked at $28.7M in Q2 2023.
  • 176 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2025.

Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.